Recalcitrant Palmoplantar Pustular Psoriasis Treated with Etanercept

Floristán, Uxúa; Feltes, Rosa; Ramírez, Paloma; Alonso, Marina; Lucas, R. de

doi:10.1111/j.1525-1470.2011.01234.x

Cited by 30 publications

(24 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3,4 PPP can present alone, or in association with psoriasis vulgaris [palmoplantar pustular psoriasis (PPPP)]. 4,[7][8][9][10][11][12] We present our experience with ustekinumab in five patients with severe refractory PPPP. 5,6 Biological agents are highly effective in moderate-to-severe psoriasis vulgaris, and their efficacy in nonpustular palmoplantar psoriasis has been shown in a clinical trial, 7 but only sporadic cases and very few reports have been published in support of their possible therapeutic efficacy in PPP and PPPP.…”

Section: Discussionmentioning

confidence: 99%

“…5,6 Biological agents are highly effective in moderate-to-severe psoriasis vulgaris, and their efficacy in nonpustular palmoplantar psoriasis has been shown in a clinical trial, 7 but only sporadic cases and very few reports have been published in support of their possible therapeutic efficacy in PPP and PPPP. 4,[7][8][9][10][11][12] We present our experience with ustekinumab in five patients with severe refractory PPPP.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of ustekinumab in refractory palmoplantar pustular psoriasis

Morales-Múnera

Vilarrasa

Puig

2013

British Journal of Dermatology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Efficacy of ustekinumab in refractory palmoplantar pustular psoriasis

Morales-Múnera

Vilarrasa

Puig

2013

British Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…In two large studies of JIA, one with a duration up to 8 years, the safety profile of etanercept was almost the same as in pediatric psoriasis, although conclusions based on different disease populations could be biased 61,62. According to several case reports and expert opinion, etanercept has also a favorable therapeutic profile in the treatment of severe erythrodermic and pustular pediatric psoriasis 20,58–60,63. It is interesting to note that 70% of participants in a European expert group consensus consider etanercept as first-line treatment of juvenile chronic plaque psoriasis due to its strong efficacy, excellent tolerability, and good safety profile 20…”

Section: Management Of Psoriasis In Adolescencementioning

confidence: 99%

Management of psoriasis in adolescence

Fotiadou¹,

Lazaridou²,

Ioannides³

2014

AHMT

View full text Add to dashboard Cite

Psoriasis is a chronic inflammatory cutaneous disorder affecting 2%–4% of the world’s population. The prevalence of the disease in childhood and adolescence ranges between 0.5% and 2%. The management of psoriasis in adolescence is an intriguing and complicated task. Given the paucity of officially approved therapies, the very limited evidence-based data from randomized controlled trials, and the absence of standardized guidelines, physicians must rely on published experience from case reports both from the field of dermatology as well as from the application of these drugs for other pediatric conditions coming from the disciplines of rheumatology, gastroenterology, and oncology. Psoriatic adolescents deal with a potentially disfiguring and lifelong disease that could permanently impair their psychological development. It must be clarified to them that psoriasis does not have a permanent cure, and therefore the main goal of treatments is to establish disease control and prolonged periods between flares. The majority of adolescents suffer from mild psoriasis, and thus they are treated basically with topical treatment modalities. Phototherapy is reserved for adolescents with mild-to-moderate plaque disease and/or guttate psoriasis when routine visits to specialized centers do not create practical problems. Systemic agents and biologics are administered to patients with moderate-to-severe plaque psoriasis, pustular psoriasis, or erythrodermic psoriasis.

show abstract

“…4 Fourteen new studies were found. 60,[68][69][70][71][72][73][74][75][76][77][78][79][80] Seven studies were exluded, 60,68,[70][71][72]74,76 because of an unclear outcome measure and/or systemic combination therapy (n = 4), 60,68,70,74 subgroup analyses of an original double-blind randomized controlled trial (RCT) 61 which was already mentioned in our previous review 4 (n = 2), 72,76 and only quality of life (Qol) outcomes of the same previously mentioned cohort (n = 1). 71 In the present review, new publications on the cohort described in the 48-week phase III double-blind RCT (LOE1b) 61 were included, containing long-term data.…”

Section: Etanerceptmentioning

confidence: 99%

Systemic treatments in paediatric psoriasis: a systematic evidence‐based update

Geel

Mul

Jager

et al. 2014

Acad Dermatol Venereol

View full text Add to dashboard Cite

In 2008, a systematic review revealed that evidence-based data on efficacy and safety of treatments in paediatric psoriasis are scarce and with low level of evidence. In recent years, publications on this topic have increased exponentially. To present a systematic, evidence-based update on the efficacy and safety of systemic treatments in paediatric psoriasis and to provide treatment recommendations, an update of the previous review was performed. PubMed, EMBASE and the Cochrane Controlled Clinical Trial Register were searched between January 2007 and March 2014 for all available literature on efficacy and safety of all systemic treatments in paediatric psoriasis. The levels of evidence were determined on the Oxford Centre for Evidence-based Medicine Levels of Evidence. The newly retrieved evidence was combined with the evidence available in the former review. Fifty-two studies were included: 36 from the former review, plus 16 new articles. New evidence on induction therapy was mainly available on fumaric acid esters (FAEs), which are shown to be effective in a subgroup of patients. Long-term (96 weeks) safety and efficacy data on etanercept were found. Prospective studies are scarce. Most conclusions are formulated on studies with low level of evidence. Of the conventional systemic treatments, methotrexate still has the most evidence albeit in a low number of patients and with a low level of evidence. FAEs seem to be effective in a subgroup of patients, with gastro-intestinal complaints, flushes and temporary shifts in leucocyte counts and liver enzymes being the main side-effects. Etanercept has still accumulated most evidence of the available systematic treatments, with a large efficacy and reassuring safety profile in a 96-week follow-up.

show abstract

Recalcitrant Palmoplantar Pustular Psoriasis Treated with Etanercept

Cited by 30 publications

References 5 publications

Efficacy of ustekinumab in refractory palmoplantar pustular psoriasis

Efficacy of ustekinumab in refractory palmoplantar pustular psoriasis

Management of psoriasis in adolescence

Systemic treatments in paediatric psoriasis: a systematic evidence‐based update

Contact Info

Product

Resources

About